PF-07985045 + cetuximab

PF-07985045 + cetuximab is an investigational combination therapy currently in Phase 1 clinical development for advanced solid tumors, especially those harboring KRAS mutations. PF-07985045 is an oral small molecule inhibitor of KRAS, a GTPase protein that is commonly mutated in a broad range of human cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), already approved for certain colorectal and head and neck cancers. The study evaluates the safety, tolerability, and potential efficacy of PF-07985045 in combination with cetuximab, focusing on advanced or metastatic tumors that have become resistant to standard therapies[1][2][3][5][7].